OCEA
Ocean Biomedical, Inc.
Set alert
- YTD
- -60.00%
- 1 year
- -90.00%
- Open
- 0.0005
- Prev close
- 0.0008
- Mkt cap
- 46.47K
- Vol
- 7.78K
- Avg vol
- 68.24K
- EPS
- -0.23
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0005
- High
- 0.0007
- Forward P/E
- -0.72
- Beta
- 1.53
- Short ratio
- 2.64
- Inst. own
- 10.54%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.79092
- 200-d avg
- 1.44
- 1y target
- 0.00
Key statistics
- Market cap
- 22.29M
- Enterprise value
- 41.39M
- Trailing P/E
- 0.00
- Forward P/E
- -0.72
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -4.35
- Beta
- 1.53
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 1.56M
- Total cash
- 31.00K
- Total debt
- 17.16M
- Return on equity
- 0.00%
- Shares outstanding
- 34.82M
- Short % of float
- 1.62%
- 50-day average
- 0.79092
- 200-day average
- 1.44
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 31, 2023 | Taglich Brothers | init | — | Speculative Buy |
| Apr 27, 2023 | EF Hutton | main | — | Buy |
| Apr 13, 2023 | EF Hutton | reit | — | Buy |
| Mar 16, 2023 | Fundamental Research Corp. | init | — | Buy |
| Mar 13, 2023 | EF Hutton | init | — | Buy |
About Ocean Biomedical, Inc.
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP. The company is based in Providence, Rhode Island. Ocean Biomedical, Inc. operates as a subsidiary of Poseidon Bio, LLC.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- oceanbiomedical.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on OCEA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AJJARAPU SURENDRA K | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 13, 2023 | 0 |
| KATHURIA CHIRINJEEV | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Feb 13, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Polar Asset Management Partners Inc. | 7.72% | 2,688,193 | 1.72M | Sep 29, 2024 |
| Vanguard Group Inc | 1.17% | 406,529 | 260.22K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.40% | 140,991 | 90.25K | Sep 29, 2024 |
| Millennium Management Llc | 0.37% | 127,562 | 81.65K | Sep 29, 2024 |
| Blackrock Inc. | 0.17% | 60,751 | 38.89K | Sep 29, 2024 |
| State Street Corporation | 0.09% | 32,800 | 21.00K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.70% | 243,673 | 155.97K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.45% | 156,202 | 99.98K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.17% | 59,158 | 37.87K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.10% | 34,144 | 21.86K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.06% | 21,585 | 13.82K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.05% | 18,319 | 11.72K | Oct 30, 2024 |